News. Analysis. Insight.™ - 100 Years of Journalistic Excellence

•

MARSHALL EDWARDS Add to My Watchlist

(NSDQ: MSHL)

0.74

+0.01 (+1.21%)

1,100

MARSHALL EDWARDS
140 Wicks Road
North Ryde, New South Wales 2113
http://www.marshalledwardsinc.com

Marshall Edwards is engaged as a developmental stage pharmaceutical company. Co.'s business purpose is the development and commercialization of drugs for the treatment of cancer. Co. is engaged in the clinical development and commercialization of a drug candidate called phenoxodiol, which Co. is testing as an application against a range of cancers. Phenoxodiol appears to target a number of key components involved in cancer cell survival and proliferation based on the emerging field of signal transduction regulation, with little or no effect on normal cells in pre-clinical testing. Co. has also licensed two other anti-cancer compounds, NV-196 and NV-143 , from a subsidiary of Novogen.

Industry	Health
Sector	Pharmaceuticals
# of Employees	-
Shares Outstanding	73.5M
Market Cap	54.3M
Enterprise Value	396.4M

52-Week High	$1.74
52-Week Low	$0.25
P/E Ratio	-4.93
EPS	-$0.15/shr
Dividend	-
Yield	-

Mr. Christopher Naughton

Chief Executive Officer; President; Subsidiary Officer

Mr. David R. Seaton

Chief Financial Officer; Secretary; Subsidiary Officer

Mr. Philip A. Johnston

Subsidiary Officer

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Stock Updates provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs